Article
ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trial.
PloS one - 1 Jan 2023
Rossios Christos, Bashir Tufail, Achison Marcus, Adamson Simon, Akpan Asangaedem, Aspray Terry, Avenell Alison, Band Margaret M, Burton Louise A, Cvoro Vera, Donnan Peter T, Duncan Gordon W, George Jacob, Gordon Adam L, Gregson Celia L, Hapca Adrian, Hume Cheryl, Jackson Thomas A, Kerr Simon, Kilgour Alixe, Masud Tahir, McKenzie Andrew, McKenzie Emma, Patel Harnish, Pilvinyte Kristina, Roberts Helen C, Sayer Avan A, Smith Karen T, Soiza Roy L, Steves Claire J, Struthers Allan D, Tiwari Divya, Whitney Julie, Witham Miles D, Kemp Paul R
Abstract excerpt
BACKGROUND: Angiotensin II (AII), has been suggested to promote muscle loss. Reducing AII synthesis, by inhibiting angiotensin converting enzyme (ACE) activity has been proposed as a method to inhibit muscle loss. The LACE clinical trial was designed to determine whether ACE inhibition would reduce further muscle loss in individuals with sarcopenia but suffered from low recruitment and returned a negative result....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.